KOD
Kodiak Sciences Inc.Company Information
- Company Name
- Kodiak Sciences Inc.
- CIK
- CIK0001468748
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- KOD: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- KOD
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-29
- Last sale
- 2026-06-04
- Shares purchased (TTM)
- 3,868,585
- Shares sold (TTM)
- 60,000
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 55,980,784
- Shares outstanding
- 62,628,596
- Ownership
- 89.39%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -11.56%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 126 | 170 | 210 | 72 | 104 | 139 | 168 | 198 | 219 | 246 | 286 | 346 | ||||||
| Prepaid Expense And Other Assets Current | 5 | 6 | 5 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 4 | 5 | ||||||
| Marketable Securities Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Assets Current | 131 | 175 | 215 | 76 | 108 | 143 | 172 | 202 | 225 | 252 | 289 | 351 | ||||||
| Restricted Cash Noncurrent | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | ||||||
| Property Plant And Equipment Net | 78 | 82 | 85 | 89 | 93 | 98 | 102 | 107 | 111 | 116 | 120 | 125 | ||||||
| Operating Lease Right Of Use Asset | 32 | 34 | 37 | 39 | 41 | 42 | 47 | 49 | 51 | 53 | 55 | 56 | ||||||
| Other Assets Noncurrent | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | ||||||
| Assets | 257 | 306 | 352 | 218 | 257 | 298 | 336 | 373 | 402 | 435 | 479 | 548 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 13 | 11 | 13 | 10 | 5 | 7 | 4 | 3 | 2 | 2 | 14 | 39 | ||||||
| Accrued Liabilities Current | 30 | 27 | 21 | 20 | 15 | 13 | 11 | 11 | 9 | 13 | 18 | 23 | ||||||
| Operating Lease Liability Current | 10 | 12 | 12 | 12 | 11 | 11 | 11 | 10 | 10 | 10 | 10 | 9 | ||||||
| Liabilities Current | 53 | 50 | 46 | 42 | 31 | 31 | 26 | 24 | 21 | 25 | 42 | 71 | ||||||
| Operating Lease Liability Noncurrent | 43 | 44 | 47 | 50 | 54 | 57 | 60 | 63 | 66 | 69 | 72 | 74 | ||||||
| Liabilities | 196 | 194 | 194 | 194 | 186 | 189 | 185 | 187 | 187 | 194 | 214 | 245 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,744 | 1,729 | 1,716 | 1,526 | 1,511 | 1,495 | 1,479 | 1,470 | 1,455 | 1,437 | 1,418 | 1,395 | ||||||
| Retained Earnings Accumulated Deficit | -1,683 | -1,617 | -1,559 | -1,502 | -1,441 | -1,386 | -1,329 | -1,285 | -1,241 | -1,196 | -1,153 | -1,093 | ||||||
| Stockholders Equity | 61 | 112 | 157 | 24 | 70 | 109 | 150 | 185 | 215 | 241 | 266 | 302 | ||||||
| Liabilities And Stockholders Equity | 257 | 306 | 352 | 218 | 257 | 298 | 336 | 373 | 402 | 435 | 479 | 548 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | ||||||
| Common Stock Shares Issued | 63 | 62 | 62 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 52 | ||||||
| Shares Outstanding | 63 | 62 | 62 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 52 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialKodiak Sciences Inc. (KOD) — SEC Financial Statements & Analysis
Kodiak Sciences Inc. (KOD) is a biological products, (no diagnostic substances) company, incorporated in DE. Kodiak Sciences Inc. trades on Nasdaq as: KOD. Kodiak Sciences Inc. (KOD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Kodiak Sciences Inc. carries a market cap of $2.44B, a P/E ratio of -10.08x, a P/B ratio of 39.94x, an enterprise value of $2.31B, and an EV/EBITDA multiple of -10.10x. On profitability, it posts a Return on Equity (ROE) of -368.37% and a Return on Assets (ROA) of -94.25%. Per share, it reports EPS of $-3.86, diluted EPS of $-3.86, free cash flow per share of $-2.55, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 21.10% year-over-year and EPS growth of 2.06% year-over-year. On the balance sheet, it maintains a current ratio of 2.49x, a quick ratio of 2.39x, working capital of $78.59M, a debt-to-equity ratio of 3.20x, a debt ratio of 0.76, an interest coverage ratio of -42382.40x, free cash flow of $-159.90M (TTM), and net debt of $-125.90M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.44B
- P/E TTM
- -10.08x
- EPS TTM
- $-3.86
- P/B TTM
- 39.94x
- ROE TTM
- -368.37%
- ROA TTM
- -94.25%
- Debt To Equity
- 3.20x
- Free Cash Flow TTM
- $-159.90M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Kodiak Sciences Inc. in?
Kodiak Sciences Inc. (KOD) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does KOD trade on?
Kodiak Sciences Inc. (KOD) trades on the Nasdaq.
Where is Kodiak Sciences Inc. incorporated?
Kodiak Sciences Inc. is incorporated in DE.
When was Kodiak Sciences Inc. (KOD)'s most recent SEC filing?
Kodiak Sciences Inc. (KOD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is KOD's market cap?
Kodiak Sciences Inc. (KOD) has a market capitalization of $2.44B as of 2026-06-30.
What is KOD's EPS (earnings per share)?
Kodiak Sciences Inc. (KOD)'s trailing twelve month EPS is $-3.86 as of 2026-06-30.
What is KOD's ROE (return on equity)?
Kodiak Sciences Inc. (KOD)'s trailing twelve month Return on Equity (ROE) is -368.37% as of 2026-06-30.
What is KOD's ROA (return on assets)?
Kodiak Sciences Inc. (KOD)'s trailing twelve month Return on Assets (ROA) is -94.25% as of 2026-06-30.
What is KOD's EV/EBITDA?
Kodiak Sciences Inc. (KOD)'s trailing twelve month EV/EBITDA is -10.10x as of 2026-06-30.